Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New 'flexible' treatment option for rheumatoid arthritis

  • Comment

A subcutaneous formulation of tocilizumab (RoActemra) has been launched, giving rheumatoid arthritis patients the option to be treated at home as well as hospital.

It is the first anti IL-6 receptor inhibitor available in a subcutaneous and intravenous version, for use with or without methotrexate.

Tocilizumab is licenced for intravenous use every four weeks and the subcutaneous formulation is administered once a week via a pre-filled syringe.

The most common adverse reactions reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, elevated blood pressure, and increased liver enzymes.

Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: “We welcome this new option which provides greater flexibility and choice for people with rheumatoid arthritis giving them the freedom to carry on with their day-to-day lives.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs